Business Description
Seres Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US81750R2013
Total Employee Number:
66Description
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.37 | |||||
Equity-to-Asset | 0.23 | |||||
Debt-to-Equity | 3.04 | |||||
Debt-to-EBITDA | 3.85 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -12.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 37.1 | |||||
3-Year Book Growth Rate | 39 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 21.78 | |||||
9-Day RSI | 32.73 | |||||
14-Day RSI | 37.73 | |||||
3-1 Month Momentum % | -22 | |||||
6-1 Month Momentum % | -58.53 | |||||
12-1 Month Momentum % | -47.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.65 | |||||
Quick Ratio | 1.65 | |||||
Cash Ratio | 1.54 | |||||
Days Sales Outstanding | 329.04 | |||||
Days Payable | 243.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.1 | |||||
Shareholder Yield % | 63.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -163.03 | |||||
Operating Margin % | -7640.98 | |||||
Net Margin % | -4088.84 | |||||
EBITDA Margin % | 1821.19 | |||||
FCF Margin % | -3694.07 | |||||
OCF Margin % | -3675.07 | |||||
ROE % | -118.53 | |||||
ROA % | -33.16 | |||||
ROIC % | -85.57 | |||||
3-Year ROIIC % | -136.14 | |||||
ROC (Joel Greenblatt) % | 20.48 | |||||
ROCE % | 14.6 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 19.78 | |||||
PS Ratio | 50.08 | |||||
PB Ratio | 2.21 | |||||
Price-to-Tangible-Book | 2.21 | |||||
EV-to-EBIT | 6.44 | |||||
EV-to-Forward-EBIT | -1.5 | |||||
EV-to-EBITDA | 5.26 | |||||
EV-to-Forward-EBITDA | -1.5 | |||||
EV-to-Revenue | 95.76 | |||||
EV-to-Forward-Revenue | 8.54 | |||||
EV-to-FCF | -2.59 | |||||
Earnings Yield (Greenblatt) % | 15.53 | |||||
FCF Yield % | -71.61 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MCRB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Seres Therapeutics Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.147 | ||
| EPS (TTM) ($) | -5.18 | ||
| Beta | 1.0038 | ||
| 3-Year Sharpe Ratio | -0.43 | ||
| 3-Year Sortino Ratio | -0.63 | ||
| Volatility % | 71.06 | ||
| 14-Day RSI | 37.73 | ||
| 14-Day ATR ($) | 0.668485 | ||
| 20-Day SMA ($) | 6.91325 | ||
| 12-1 Month Momentum % | -47.45 | ||
| 52-Week Range ($) | 5.31 - 29.98 | ||
| Shares Outstanding (Mil) | 9.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Seres Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Seres Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 08:30 | In 116 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 115 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | In 25 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 24 days | ||
| Seres Therapeutics Corporate Updates | 2026-07-08 08:30 | 8.14 (+6.41%) | ||
| General meeting for 2026 | 2026-07-08 08:00 | 8.14 (+6.41%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 15:30 | 7.59 (+0.80%) | ||
| First quarter earnings results for 2026 | 2026-05-05 07:00 | 7.69 (+0.79%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 07:00 | 8.93 (-0.78%) | ||
| Annual report for 2025 | 2026-03-12 | 8.93 (-0.78%) |
Show
Entries
Seres Therapeutics Inc Frequently Asked Questions
What is Seres Therapeutics Inc(MCRB)'s stock price today?
The current price of MCRB is $6.11. The 52 week high of MCRB is $29.98 and 52 week low is $5.31.
When is next earnings date of Seres Therapeutics Inc(MCRB)?
The next earnings date of Seres Therapeutics Inc(MCRB) is 2026-08-06 Est..
Does Seres Therapeutics Inc(MCRB) pay dividends? If so, how much?
Seres Therapeutics Inc(MCRB) does not pay dividend.
Guru Commentaries on NAS:MCRB
No articles.
Press Release
Articles on Seres Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers